AC8 – Auscann Group Holdings Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

AusCann Group Holdings Limited is an Australia-based company, which is focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Neuvis is its controlled-dose technology platform, which delivers cannabinoids (CBD) to human patients, with the first product in the range being a THC:CBD hard-shell capsule in a 1:1 ratio, in both a 2.5mg and 10mg strength. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol and cannabidiol whole plant extracts in a ratio to target pain and inflammation in dogs. DermaCann is its CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. MicroMAX is an encapsulation technology, which helps to enhance the delivery of cannabis-based animal health products. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Responses